Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATIS-ICAS: Rivaroxaban + Aspirin vs Clopidogrel + Aspirin for Recurrent Stroke Prevention in ICAD
NCT07468448Phase 3Not yet recruiting
- Sponsor
- Population Health Research Institute
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rivaroxaban in ischemic stroke, intracranial atherosclerosis (ICAD), sponsored by Population Health Research Institute. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
ischemic strokeintracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT07468448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468448.